Moderna

$33.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.09 (-3.13%) As of 3:30 PM EDT today
-$1.09 (-3.13%) Today

Why Robinhood?

You can buy or sell Moderna and other stocks, options, ETFs, and crypto commission-free!

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. Read More The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Employees
830
Headquarters
Cambridge, Massachusetts
Founded
2010
Market Cap
9.76B
Price-Earnings Ratio
Dividend Yield
Average Volume
12.44M
High Today
$35.19
Low Today
$33.33
Open Price
$34.90
Volume
9.48M
52 Week High
$36.00
52 Week Low
$11.54

Collections

MRNA News

BenzingaApr 3

Moderna Coronavirus Vaccine Phase 2 Trials Could Start In Spring, Chairman Says

The second phase of the clinical trials of the novel coronavirus (COVID-19) vaccine of Moderna Inc. (NASDAQ: MRNA) could begin in spring, the biotechnology comp
599
BenzingaApr 2

Moderna Coronavirus Vaccine Clinical Trials Are 'On Track,' White House Task Force's Fauci Says

The clinical trials of Moderna Inc.'s (NASDAQ: MRNA) novel coronavirus (COVID-19) vaccine are "on track," according to National Institute of Allergy and Infecti
214
ReutersMar 31

J&J, Moderna sign deals with U.S. to produce huge quantity of possible coronavirus vaccines

(Reuters) - The U.S. government has cut deals with Johnson & Johnson (JNJ.N) and Moderna Inc (MRNA.O) and said it is in talks with at least two other companies
2,287

MRNA Earnings

-$0.44
-$0.29
-$0.15
$0.00
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
per share
Actual
Expected May 6, Pre-Market

People Also Bought

You May Also Like

Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.